<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) is the only established precursor lesion in the development of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (EAC) and it increases the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> by 11-fold </plain></SENT>
<SENT sid="1" pm="."><plain>It is regarded as a complication of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>There is an ever-increasing body of knowledge on the pathogenesis, diagnosis, treatment, and surveillance of BE and its associated <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>In this review, we summarize the latest advances in BE research and clinical practice in the past 2 years </plain></SENT>
<SENT sid="4" pm="."><plain>It is critical to understand the molecular underpinnings of this disorder to comprehend the clinical outcomes of the disease </plain></SENT>
<SENT sid="5" pm="."><plain>For clinical gastroenterologists, there is also continuous growth of endoscopic approaches which is daunting, and further improvements in the detection and treatment of BE and early EAC are anticipated </plain></SENT>
<SENT sid="6" pm="."><plain>In the future, we may see the increased role of biomarkers, both molecular and imaging, in both diagnostic and therapeutic strategies for BE </plain></SENT>
</text></document>